After BioNTech SE and Pfizer, Moderna and NIH, 3rd mRNA Covid vaccine player CureVac now partners with fellow German company Bayer...

Infectious diseases have been largely forgotten by Pharma R&D and investors, as chronic diseases, cancer and rare diseases gave better...

While Brexit goal is officially to "take back control", UK MedTech may have to choose between aligning regulatory process with EU or US....

After granting €252M to CureVac, the German government has awarded €375M to BioNTech. BioNtech announcement: https://lnkd.in/dKinEe4...

Usage of Biosimilars has increased significantly in Europe, while usage in the US has been lagging behind. Now, Biosimilars are finally...

The $ 20+ billion Psoriasis treatment market has been dominated by AbbVie's Humira. But things might change soon. After beating J&J’s...

Launching in pandemic time requires bold moves, such as those taken by Esperion, Horizon, Eisai or Clarus: - remote interactions with...

Launching in post-Covid time requires creativity. For its new lip-filler, Galderma is providing digital materials for healthcare...

How should Medtech companies re-visit launch priorities in post-Covid world ? By focusing on those with compelling value proposition and...